Have a feature idea you'd love to see implemented?
Let us know!
ITCI Intra-Cellular Therapies Inc
Price (delayed)
$85.45
Market cap
$9.06B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.87
Enterprise value
$8.61B
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this
Highlights
The equity has surged by 91% year-on-year
The EPS has grown by 46% YoY
The net income is up by 44% YoY but it is down by 2.5% from the previous quarter
ITCI's quick ratio is up by 20% YoY but it is down by 3.9% from the previous quarter
Key stats
What are the main financial stats of ITCI
Market
Valuations
Earnings
Shares outstanding
106.02M
Market cap
$9.06B
Enterprise value
$8.61B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.89
Price to sales (P/S)
14.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.03
Revenue
$613.73M
EBIT
-$85.13M
EBITDA
-$84.6M
Free cash flow
-$62.91M
Per share
Balance sheet
Liquidity
EPS
-$0.87
Free cash flow per share
-$0.59
Book value per share
$10.83
Revenue per share
$5.8
TBVPS
$12.52
Total assets
$1.32B
Total liabilities
$179.62M
Debt
$17.71M
Equity
$1.14B
Working capital
$1.11B
Debt to equity
0.02
Current ratio
7.66
Quick ratio
6.95
Net debt/EBITDA
5.3
Margins
Efficiency
Dividend
EBITDA margin
-13.8%
Gross margin
92.3%
Net margin
-14.1%
Operating margin
-19.8%
Return on assets
-8.4%
Return on equity
-9.9%
Return on invested capital
-15.8%
Return on capital employed
-7.3%
Return on sales
-13.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ITCI stock price
How has the Intra-Cellular Therapies stock price performed over time
Intraday
-0.22%
1 week
-2.49%
1 month
11.1%
1 year
45.99%
YTD
19.31%
QTD
16.78%
Financial performance
How have Intra-Cellular Therapies's revenue and profit performed over time
Revenue
$613.73M
Gross profit
$566.47M
Operating income
-$121.62M
Net income
-$86.37M
Gross margin
92.3%
Net margin
-14.1%
The net margin has surged by 62% year-on-year and by 5% since the previous quarter
The operating margin has soared by 52% YoY
The revenue has grown by 46% YoY and by 9% from the previous quarter
The gross profit has grown by 45% YoY and by 8% from the previous quarter
Growth
What is Intra-Cellular Therapies's growth rate over time
Valuation
What is Intra-Cellular Therapies stock price valuation
P/E
N/A
P/B
7.89
P/S
14.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.03
The EPS has grown by 46% YoY
The equity has surged by 91% year-on-year
ITCI's P/B is 13% above its 5-year quarterly average of 7.0 but 12% below its last 4 quarters average of 9.0
The stock's price to sales (P/S) is 99% less than its 5-year quarterly average of 1670.1 but 11% more than its last 4 quarters average of 13.3
The revenue has grown by 46% YoY and by 9% from the previous quarter
Efficiency
How efficient is Intra-Cellular Therapies business performance
The ROS has soared by 62% YoY and by 6% from the previous quarter
Intra-Cellular Therapies's ROA has soared by 61% YoY and by 13% from the previous quarter
The ROE has soared by 60% YoY and by 14% from the previous quarter
ITCI's return on invested capital is up by 45% year-on-year and by 7% since the previous quarter
Dividends
What is ITCI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ITCI.
Financial health
How did Intra-Cellular Therapies financials performed over time
Intra-Cellular Therapies's total assets has soared by 85% YoY
The total liabilities has soared by 54% YoY and by 2.1% from the previous quarter
The debt is 98% smaller than the equity
The equity has surged by 91% year-on-year
ITCI's debt to equity is down by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.